Research analysts at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Saturday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.

Acorda Therapeutics Trading Up 3.8 %

Acorda Therapeutics stock opened at $0.41 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 2.10. The business's fifty day simple moving average is $0.44 and its two-hundred day simple moving average is $0.91. Acorda Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.99. The company has a market capitalization of $5.50 million, a price-to-earnings ratio of -0.05 and a beta of 0.45.

Institutional Investors Weigh In On Acorda Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC boosted its holdings in Acorda Therapeutics by 22.3% in the fourth quarter. Acadian Asset Management LLC now owns 467,739 shares of the biopharmaceutical company's stock worth $1,116,000 after acquiring an additional 85,335 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Acorda Therapeutics by 27.4% in the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock worth $420,000 after acquiring an additional 194,100 shares in the last quarter. Millennium Management LLC boosted its holdings in Acorda Therapeutics by 661.2% in the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after acquiring an additional 270,588 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Acorda Therapeutics in the second quarter worth $68,000. Finally, Prudential Financial Inc. purchased a new position in shares of Acorda Therapeutics in the second quarter worth $28,000. 50.24% of the stock is owned by institutional investors.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

Featured Stories

• Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
• Can Electronic Arts Buck the Downturn in Videogaming?
• Dollar General is the Big Fish in Little Ponds Across the U.S.
• Here's Why the CPI Report will Dictate the Market Bottom
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.